Page of

Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer 

Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer
Chapter:
Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer
Source:
Ovarian Cancer Immunotherapy
Author(s):

Samir A. Farghaly

DOI:
10.1093/med/9780190248208.003.0005

The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficacy of adoptive cell therapy (ACT) in EOC. The aim of this chapter is to present an overview of ACT in EOC, focusing on Human Leukocyte Antigen (HLA)-restricted tumor infiltrating lymphocytes and MHC-independent immune effectors such as natural killer and cytokine-induced killer. The available data suggest that ACT may provide the best outcome in patients with low tumor burden, minimal residual disease, or maintenance therapy. Further preclinical studies and clinical trials are needed.

Sign In

Copyright © 2021. All rights reserved.